A Brief Review of Pharmacoeconomics and Its Importance in Healthcare

Home > 2025, Vol. 13 No. 01 > A Brief Review of Pharmacoeconomics and Its Importance in Healthcare

Published: October 20, 2025

Download PDF

Download HTML

Authors

Arti Saini and Shivam Sharma

DOI Number
https://doi.org/10.15415/jptrm.2025.131005

Keywords
Cost-effectiveness, Drugs, Expenses, Health economics, Pharmacoeconomics

Abstract

Background: Assessing health interventions today requires the use of economic knowledge due to the growing complexity and high cost of healthcare. Pharmacoeconomics, a branch of health economics, assesses the value of pharmaceutical goods and services by weighing their costs and benefits. Pharmacoeconomic analysis plays a critical role in supporting evidence-based decision-making and policy-making as healthcare expenditures throughout the globe continue to grow.

Purpose: The objective of this study is to provide a concise overview of pharmacoeconomics, its primary methodologies, and its growing significance within healthcare systems.

Methods: This literature review, covering publications from 2014 to 2025, analyzed peer-reviewed articles, policy documents, and textbooks on pharmacoeconomics. The review employed comparative frameworks such as cost minimization, cost-effectiveness, cost-utility, and cost-benefit analyses.

Results: Pharmacoeconomic analysis is increasingly being included in national and international healthcare systems to ensure efficient resource management. It significantly influences the evaluation of rival treatment options and the judgments about medication reimbursement. Common methodologies encompass cost-effectiveness and cost-utility evaluations, among others. Countries such as the UK, Canada, and Australia have institutionalized pharmacoeconomic evaluations through the establishment of organizations like the National Institute for Health and Care Excellence (NICE), the Canadian Agency for Drugs and Technologies in Health (CADTH), and the Pharmaceutical Benefits Advisory Committee (PBAC).

Conclusion: Pharmacoeconomics is a crucial component of the modern healthcare landscape, facilitating the optimal allocation of limited financial resources to enhance health outcomes. It assists policymakers, physicians, and payers in making decisions informed by costs and clinical outcomes. As healthcare costs continue to rise, the role of pharmacoeconomics in policymaking and practice will become increasingly essential.

References

Ahmad, A., Chang, J., Chung, H., Mohanta, G., Parimilakrishnan, S., & Patel, I. (2013). The role of pharmacoeconomics in current Indian healthcare system. Journal of Research in Pharmacy Practice, 2(1), 3. https://doi.org/10.4103/2279-042X.114081
Al Meslamani, A. Z. (2024). Barriers to digital endpoints in data collection in low- and middle-income countries. Expert Review of Pharmacoeconomics & Outcomes Research, 24(6), 701–703. https://doi.org/10.1080/14737167.2024.2331047
Alzarea, A. I., Khan, Y. H., Alanazi, A. S., Butt, M. H., Almalki, Z. S., Alahmari, A. K., Alsahali, S., & Mallhi, T. H. (2022). Barriers and facilitators of pharmacoeconomic studies: A review of evidence from the Middle Eastern countries. International Journal of Environmental Research and Public Health, 19(13), 7862. https://doi.org/10.3390/ijerph19137862
Angello, J. T., Voytovich, R. M., & Jan, S. A. (1997). A cost/efficacy analysis of oral antifungals indicated for the treatment of onychomycosis: Griseofulvin, itraconazole, and terbinafine. The American Journal of Managed Care, 3(3), 443–450.
Antibacterial prescribing for RTIs varies widely across Europe. (2013). PharmacoEconomics & Outcomes News, 401(1), 7. https://doi.org/10.1007/BF03275904
Arenas-Guzman, R., Tosti, A., Hay, R., & Haneke, E. (2005). Pharmacoeconomics—An aid to better decision-making. Journal of the European Academy of Dermatology and Venereology, 19(Suppl. 1), 34–39. https://doi.org/10.1111/j.1468-3083.2005.01285.x
Asher, I., & Pearce, N. (2014). Global burden of asthma among children. The International Journal of Tuberculosis and Lung Disease, 18(11), 1269–1278. https://doi.org/10.5588/ijtld.14.0170
Augustine, N. R., Madhavan, G., & Nass, S. J. (2017). Making medicines affordable: A national imperative (Vol. 1, pp. 1–234). National Academies Press. https://doi.org/10.17226/24946
Bodrogi, J., & Kaló, Z. (2010). Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development. British Journal of Pharmacology, 159(7), 1367–1373. https://doi.org/10.1111/j.1476-5381.2009.00550.x
Buyx, A. M., Friedrich, D. R., & Schöne-Seifert, B. (2011). Ethics and effectiveness: Rationing healthcare by thresholds of minimum effectiveness. BMJ, 342, d54. https://doi.org/10.1136/bmj.d54
Choi, J. S., Lee, W. B., & Rhee, P. L. (2013). Cost-benefit analysis of electronic medical record system at a tertiary care hospital. Healthcare Informatics Research, 19(3), 205–211. https://doi.org/10.4258/hir.2013.19.3.205
Di Bona, D., Bilancia, M., Albanesi, M., Caiaffa, M. F., & Macchia, L. (2020). Cost-effectiveness of grass pollen allergen immunotherapy in adults. Allergy, 75(9), 2319–2329. https://doi.org/10.1111/all.14246
Di Bona, D., Plaia, A., Leto-Barone, M. S., La Piana, S., & Di Lorenzo, G. (2012). Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis-based comparison. Journal of Allergy and Clinical Immunology, 130(5), 1097–1107. https://doi.org/10.1016/j.jaci.2012.08.012
Doron, S., & Davidson, L. E. (2011). Antimicrobial stewardship. Mayo Clinic Proceedings, 86(11), 1113–1123. https://doi.org/10.4065/mcp.2011.0358
Dranitsaris, G., & Ellis, A. K. (2014). Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: An indirect analysis of efficacy, safety, and cost. Journal of Evaluation in Clinical Practice, 20(3), 225–238. https://doi.org/10.1111/jep.12112
Ekanayake, P., Hupfeld, C., & Mudaliar, S. (2020). Sodium-glucose cotransporter type 2 (SGLT-2) inhibitors and ketogenesis: The good and the bad. Current Diabetes Reports, 20(12), 72. https://doi.org/10.1007/s11892-020-01359-z
Ellis, C. N., Reiter, K. L., Wheeler, J. R. C., & Fendrick, A. M. (2002). Economic analysis in dermatology. Journal of the American Academy of Dermatology, 46(2), 271–283. https://doi.org/10.1067/mjd.2002.119566
Ghinea, N., Lipworth, W., & Kerridge, I. (2016). Propaganda or the cost of innovation? Challenging the high price of new drugs. BMJ, 352, i1284. https://doi.org/10.1136/bmj.i1284
Gold, M. R., Stevenson, D., & Fryback, D. G. (2002). HALYs and QALYs and DALYs, oh my: Similarities and differences in summary measures of population health. Annual Review of Public Health, 23, 115–134. https://doi.org/10.1146/annurev.publhealth.23.100901.140513
Guerin, P. J., Singh-Phulgenda, S., & Strub-Wourgaft, N. (2020). The consequence of COVID-19 on the global supply of medical products: Why Indian generics matter for the world. F1000Research, 9, 225. https://doi.org/10.12688/f1000research.23057.1
Hayduchok, I. G., Shapovalova, V. O., Ishcheikin, K. E., Chopyak, V. V., Jr., S. V. V., & Shapovalov, V. V. (2021). Pharmacoeconomic approaches for pharmacotherapy of rheumatoid arthritis. Likars’ka Sprava, 1–2, 70–79. https://doi.org/10.31640/jvd.1-2.2021(11)
Hlatky, M. A., Owens, D. K., & Sanders, G. D. (2006). Cost-effectiveness as an outcome in randomized clinical trials. Clinical Trials, 3(6), 543–551. https://doi.org/10.1177/1740774506073105
Hu, J., & Mossialos, E. (2016). Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts. Health Policy, 120(5), 519–534. https://doi.org/10.1016/j.healthpol.2016.03.014
Humphrey, K. M., Cork, M. J., & Haycox, A. (1998). A retrospective cost-effectiveness analysis of the treatment of onychomycosis in general practice. The British Journal of Dermatology, 139(4), 660–664. https://doi.org/10.1046/j.1365-2133.1998.02463.x
India Pharmaceutical Market Size, Share and Growth, 2033. (n.d.). IMARC Group. Retrieved September 27, 2025, from https://www.imarcgroup.com/india-pharmaceutical-market
Indian Pharmaceutical Industry: Creating global impact. (2025). Pharmaceutical Engineering. Retrieved September 24, 2025, from https://ispe.org/pharmaceutical-engineering/march-april-2025/indian-pharmaceutical-industry-creating-global-impact
John, N. N., Krishnan, A., Midhun, J. V., & Juan, R. (2020). A study to evaluate pharmacoeconomics of antihypertensive drugs in a tertiary care teaching hospital. Journal of Drug Delivery and Therapeutics, 10(4-S), 176–180. https://doi.org/10.22270/jddt.v10i4-s.4227
Joshi, S. S., Shetty, Y. C., & Karande, S. (2019). Generic drugs: The Indian scenario. Journal of Postgraduate Medicine, 65(2), 67–70. https://doi.org/10.4103/jpgm.jpgm_420_18
Kawauchi, H., Yanai, K., Wang, D. Y., Itahashi, K., & Okubo, K. (2019). Antihistamines for allergic rhinitis treatment from the viewpoint of nonsedative properties. International Journal of Molecular Sciences, 20(1), 213. https://doi.org/10.3390/ijms20010213
Kruk, M. E., Gage, A. D., Arsenault, C., Jordan, K., Leslie, H. H., Roder-DeWan, S., Adeyi, O., Barker, P., Daelmans, B., Doubova, S. V., English, M., Elorrio, E. G., Guanais, F., Gureje, O., Hirschhorn, L. R., Jiang, L., Kelley, E., Lemango, E. T., Liljestrand, J., … Pate, M. (2018). High-quality health systems in the Sustainable Development Goals era: Time for a revolution. The Lancet Global Health, 6(11), e1196–e1252. https://doi.org/10.1016/s2214-109x(18)30386-3
Kumar, S., & Preetha, G. S. (2012). Health promotion: An effective tool for global health. Indian Journal of Community Medicine, 37(1), 5–12. https://doi.org/10.4103/0970-0218.94009
Lam, W. Y., & Fresco, P. (2015). Medication adherence measures: An overview. BioMed Research International, 2015, 217047. https://doi.org/10.1155/2015/217047
McInnes, I. B., & Schett, G. (2011). The pathogenesis of rheumatoid arthritis. The New England Journal of Medicine, 365(23), 2205–2219. https://doi.org/10.1056/nejmra1004965
Meena, D. K., & Mathaiyan, J. (2025). Assessment of drug inventory using ABC–VED matrix analysis in selected public health facilities of Puducherry, India. Journal of Family Medicine and Primary Care, 14(4), 1389–1395. https://doi.org/10.4103/jfmpc.jfmpc_1544_24
NHA | Official website Ayushman Bharat Digital Mission. (n.d.). Government of India. Retrieved September 27, 2025, from https://abdm.gov.in/
Pereira, M., Lunet, N., Azevedo, A., & Barros, H. (2009). Differences in prevalence, awareness, treatment, and control of hypertension between developing and developed countries. Journal of Hypertension, 27(5), 963–975. https://doi.org/10.1097/hjh.0b013e3283282f65
Pharmacoeconomics and its impact on Ayushman Bharat projects in rural India. (n.d.). World Journal of Pharmaceutical Research. Retrieved September 24, 2025, from https://www.wisdomlib.org/science/journal/world-journal-of-pharmaceutical-research/d/doc1380340.html
Rahman, W., Solinsky, P. J., Munir, K. M., & Lamos, E. M. (2019). Pharmacoeconomic evaluation of sodium-glucose transporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy, 20(2), 151–161. https://doi.org/10.1080/14656566.2018.1543408
Ramezani, M., Bakhtiari, A., Daroudi, R., Mobinizadeh, M., Fazaeli, A. A., Olyaeemanesh, A., Rabiee, H. R., Mostafavi, H., Sazgarnejad, S., Bordbar, S., & Takian, A. (2025). Applications of artificial intelligence and the challenges in health technology assessment: A scoping review and framework with a focus on economic dimensions. Health Economics Review, 15(1), 1–11. https://doi.org/10.1186/s13561-025-00645-4
Rawal, L. B., Tapp, R. J., Williams, E. D., Chan, C., Yasin, S., & Oldenburg, B. (2012). Prevention of type 2 diabetes and its complications in developing countries: A review. International Journal of Behavioral Medicine, 19(2), 121–133. https://doi.org/10.1007/s12529-011-9162-9
Strategy document on National Medical Devices Policy, 2023. (n.d.). Department of Pharmaceuticals, Government of India. Retrieved September 24, 2025, from https://pharma-dept.gov.in/policy/strategy-document-national-medical-devices-policy-2023
Tannoury, M., & Attieh, Z. (2017). The influence of emerging markets on the pharmaceutical industry. Current Therapeutic Research, 86, 19–24. https://doi.org/10.1016/j.curtheres.2017.04.005
Thokala, P., Srivastava, T., Smith, R., Ren, S., Whittington, M. D., Elvidge, J., Wong, R., & Uttley, L. (2023). Living health technology assessment: Issues, challenges, and opportunities. PharmacoEconomics, 41(3), 227–237. https://doi.org/10.1007/s40273-022-01229-4

How to Cite

Arti Saini and Shivam Sharma. A Brief Review of Pharmacoeconomics and Its Importance in Healthcare. J. Pharm. Technol. Res. Manag.. 2025, 13, 58-68

A Brief Review of Pharmacoeconomics and Its Importance in Healthcare

Current Issue

Periodicity	Biannually
Issue-1	June
Issue-2	December
ISSN Print	2321-2217
ISSN Online	2321-2225
RNI No.	CHAENG/2013/50088

This work is licensed under a Creative Commons Attribution 4.0 International License.

Articles in Journal of Pharmaceutical Technology, Research and Management (J. Pharm. Tech. Res. Management) by Chitkara University Publications are Open Access articles that are published with licensed under a Creative Commons Attribution- CC-BY 4.0 International License. Based on a work at https://jptrm.chitkara.edu.in/. This license permits one to use, remix, tweak and reproduction in any medium, even commercially provided one give credit for the original creation.

View Legal Code of the above-mentioned license, https://creativecommons.org/licenses/by/4.0/legalcode

View Licence Deed here https://creativecommons.org/licenses/by/4.0/